CA

Carnegie Asset Management

Europe, Hovedstaden, Denmark, Copenhagen

Description

Carnegie Asset Management is a focused and independent asset manager. Their objective is to deliver consistent, long term asset growth for

Investor Profile

Carnegie Asset Management has made 6 investments, with 0 in the past 12 months and 17% as lead.

Stage Focus

  • Series C (50%)
  • Series B (33%)
  • Series Unknown (17%)

Country Focus

  • Switzerland (33%)
  • Canada (33%)
  • United States (33%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Genetics
  • Life Science
  • Medical Device
  • Health Diagnostics
  • Business Development
  • Information Technology
  • Software
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Carnegie Asset Management frequently co-invest with?

Gimv
Europe, Antwerpen, Belgium, Antwerpen
Co-Investments: 2
BioMedPartners
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 1
HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 2
Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 1
3i Group
Europe, England, United Kingdom, London
Co-Investments: 2
NGN Capital
North America, New York, United States, New York
Co-Investments: 2
MF
Europe, Stockholms Lan, Sweden, Stockholm
Co-Investments: 2
Dow
North America, Michigan, United States, Midland
Co-Investments: 2
HI
Europe, Baden-Wurttemberg, Germany, Heidelberg
Co-Investments: 1
Neomed Management
Europe, Oslo, Norway, Oslo
Co-Investments: 1

What are some of recent deals done by Carnegie Asset Management?

Santhera Pharmaceuticals

Liestal, Basel-Landschaft, Switzerland

Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.

BiotechnologyHealth CarePharmaceutical
Series COct 5, 2006
Amount Raised: $19,041,816
Genizon BioSciences

Montreal, Quebec, Canada

Genizon Biosciences discovers genes and biomarkers in common diseases using genome-wide association studies.

BiotechnologyGeneticsLife ScienceMedical Device
Series UnknownMar 29, 2006
Amount Raised: $12,000,000
Santhera Pharmaceuticals

Liestal, Basel-Landschaft, Switzerland

Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.

BiotechnologyHealth CarePharmaceutical
Series BDec 20, 2005
Amount Raised: $18,997,524
Genizon BioSciences

Montreal, Quebec, Canada

Genizon Biosciences discovers genes and biomarkers in common diseases using genome-wide association studies.

BiotechnologyGeneticsLife ScienceMedical Device
Series BDec 13, 2004
Amount Raised: $9,043,138
Agensys

Santa Monica, California, United States

Agensys offers products to treat various tumors as well as prostate, pancreatic and bladder cancers.

BiotechnologyHealth DiagnosticsPharmaceutical
Series CMar 4, 2002
Amount Raised: $42,800,000
ZoomON

San Jose, California, United States

ZoomON, a provider of flexible vector graphics solutions for business-to-business applications in Web and wireless environments.

Business DevelopmentInformation TechnologySoftwareWireless
Series CJun 21, 2000
Amount Raised: $8,000,000